An anti-GD2 aptamer-based bifunctional spherical nucleic acid nanoplatform for synergistic therapy targeting MDM2 for retinoblastoma

Keyphrases

• Retinoblastoma 100%
• Nanoplatform 100%
• Aptamer-based 100%
• Murine Double Minute 2 (MDM2) 100%
• Anti-GD2 100%
• Bifunctional 100%
• Synergistic Therapy 100%
• Spherical nucleic Acids 100%
• Small Interfering RNA (siRNA) 44%
• Retinoblastoma Cells 33%
• Precision Medicine 22%
• Clinical Practice 22%
• Aptamer 22%
• NVP-CGM097 22%
• Cholesterol 11%
• Glutathione 11%
• Tumor 11%
• Antitumor Effect 11%
• Clinical Manifestations 11%
• Intravitreal Injection 11%
• Protein Content 11%
• Endocytosis 11%
• P53 Protein 11%
• Cell Apoptosis 11%
• Tumor-bearing Mice 11%
• Self-assembly 11%
• Amphiphiles 11%
• Pathological Analysis 11%
• Fundus 11%
• Pediatric Tumors 11%
• Hepatotoxicity 11%
• Active Agent 11%
• Specific Recognition 11%
• Melphalan 11%
• Specific Delivery 11%
• Nucleic Acid Therapeutics 11%
• Retinoblastoma 1 11%
• Hematology Analyzer 11%
• Oncogenic Factor 11%
• MDM2/p53 Pathway 11%
• Glutathione-responsive 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Retinoblastoma 100%
• Aptamer 100%
• Nucleic Acid 100%
• Synergistic Therapy 100%
• Small Interfering RNA 40%
• Neoplasm 20%
• Glutathione 20%
• Protein P53 20%
• Solid Malignant Neoplasm 10%
• Carcinogenesis 10%
• Amphiphile 10%
• Hepatotoxicity 10%
• Intravitreal Administration 10%
• Melphalan 10%